Compare SYNX & INBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SYNX | INBS |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 5.3M |
| IPO Year | 2024 | N/A |
| Metric | SYNX | INBS |
|---|---|---|
| Price | $1.06 | $8.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 97.8K | ★ 7.2M |
| Earning Date | 02-23-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,003,000.00 | $3,292,042.00 |
| Revenue This Year | $32.35 | $778.48 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 3.26 |
| 52 Week Low | $0.73 | $4.03 |
| 52 Week High | $4.55 | $27.50 |
| Indicator | SYNX | INBS |
|---|---|---|
| Relative Strength Index (RSI) | 47.92 | 47.25 |
| Support Level | $1.06 | $8.85 |
| Resistance Level | $1.27 | $9.97 |
| Average True Range (ATR) | 0.08 | 2.94 |
| MACD | -0.00 | -0.98 |
| Stochastic Oscillator | 23.08 | 4.68 |
Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.